AC Immune (ACIU) Interest Expenses (2015 - 2026)
AC Immune (ACIU) posted quarterly Interest Expenses of -$83005.3 for Q1 2026, down 38.2% year-over-year from -$134313.8 in Q1 2025, and up 80.37% quarter-over-quarter from -$422895.4 in Q4 2025.
Powered by 
Analysis
AC Immune (ACIU) Interest Expenses (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Interest Expenses for 12 consecutive years, with -$83005.3 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 38.2% year-over-year to -$83005.3; the TTM figure through Mar 2026 stood at -$623800.2 (down 536.03% YoY), while the FY2025 annual figure was -$230370.5, down 51.74% from the prior year.
- Interest Expenses rose to -$83005.3 in Q1 2026 per ACIU's latest filing, from -$422895.4 in the prior quarter.
- Across five years, Interest Expenses topped out at $367517.6 in Q4 2023 and bottomed at -$422895.4 in Q4 2025.
- Historically, Interest Expenses has averaged -$42733.3 across 5 years, with a median of -$41244.6 in 2024.
- Annual changes were most pronounced in 2023 — Interest Expenses surged 35305.57% — and 2025, when it plunged 1222.63%.
- AC Immune's Interest Expenses stood at $1038.0 in 2022, then surged by 35305.57% to $367517.6 in 2023, then plunged by 89.75% to $37670.2 in 2024, then slumped by 1222.63% to -$422895.4 in 2025, then soared by 80.37% to -$83005.3 in 2026.
- Business Quant data shows ACIU's Interest Expenses at -$83005.3 in Q1 2026, -$422895.4 in Q4 2025, and -$57505.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - | -77,179.59 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -77,179.59 |
| Mar 31, 2026 | -83,005.30 |
| Dec 31, 2025 | -52,549.13 |
| Sep 30, 2025 | -57,505.04 |
| Jun 30, 2025 | -60,394.51 |
| Mar 31, 2025 | -60,061.53 |
| Dec 31, 2024 | -34,245.66 |
| Sep 30, 2024 | -38,088.84 |
| Jun 30, 2024 | -37,596.98 |
| Mar 31, 2024 | -41,244.56 |
| Dec 31, 2023 | -29,311.22 |
| Sep 30, 2023 | -29,435.97 |
| Jun 30, 2023 | -30,028.74 |
| Mar 31, 2023 | -104,872.77 |
| Dec 31, 2022 | 1,038.02 |
| Sep 30, 2022 | -79,730.16 |
| Jun 30, 2022 | -130,824.92 |
| Mar 31, 2022 | -166,752.49 |
| Dec 31, 2021 | -187,618.86 |
| Sep 30, 2021 | -197,132.37 |